CORRECT and REPLACE Biocept’s CNSide Cerebrospinal Fluid Assay helps monitor response to treatment and detect actionable biomarkers in patients with metastatic breast cancer

0

Poster of the case series to be presented at the annual meeting of the Society for Neuro-Oncology

SAN DIEGO, November 18, 2021– (BUSINESS WIRE) – Third paragraph, sixth sentence of the release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six out of eleven using cytology. (Instead of CNSide, CSF tumor cells were detected in all nine measurements taken, compared to five out of nine using cytology.)

The updated version reads as follows:

THE ASSAY OF BIOCEPT CEREBROSPINAL CNSIDE LIQUID HELPS MONITOR THE RESPONSE TO TREATMENT AND DETECTS ACTIONABLE BIOMARKERS IN PATIENTS WITH METASTATIC BREAST CANCER

Poster of the case series to be presented at the annual meeting of the Society for Neuro-Oncology

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic tests, products and services, today announced the presentation of a multi-institutional case series showing that its fluid test Cerebrospinal CNSide ™ helps physicians monitor response to treatment and detect workable mutations in patients with metastatic breast cancer and leptomeningeal disease (LMD). The poster will be on display virtually at the Society for Neuro-Oncology’s annual meeting in Boston on November 19, 2021, 7:30 p.m. to 9:30 p.m. ET, and Biocept will be exhibiting at booth # 303.

Breast cancer is one of the most common cancers associated with LMD, a devastating complication in which the cancer spreads to the membrane surrounding the brain and spinal cord. The current standard of care for the diagnosis of LMD is based on clinical assessment, imaging, and cytology, which have limited sensitivity. Median survival after a diagnosis of LMD is only two to three months.

The case series included four breast cancer patients, aged 32 to 57, with suspected LMD who were treated at four different institutions. CNSide and cytology have been used in parallel to detect tumor cells in cerebrospinal fluid at the time of diagnosis and throughout treatment. CNSide has also been used to determine the number of tumor cells and the presence of HER2 amplification to help guide treatment. At the time of diagnosis, CNSide detected cancer cells in three out of three patients, compared to two out of three patients for cytology. (The fourth patient was diagnosed before CNSide was available.) CNSide detected CSF tumor cells in all eleven measurements taken, compared to six out of eleven using cytology. Throughout treatment, CNSide showed a decrease in CSF tumor cells in all four patients, ranging from 99.7% to 100%, which corresponds to an improvement in clinical response.

“Having a quantitative test that provides tumor cell counts, rather than just a positive or negative result, is a major breakthrough in the management of patients with leptomeningeal disease,” said Priya Kumthekar, MD, neuro-oncologist and associate professor of neurology at Northwestern Feinberg School of Medicine, who will present the poster for the case series. “A positive cytology result may suggest that the patient is not responding to treatment, which could lead to treatment discontinuation or modification. As shown in this series of cases, the quantitative results of CNSide can show that in fact, the number of tumor cells has decreased significantly. indicating that the patient is responding, and treatment should be continued. “

“These cases illustrate the value of CNSide in monitoring response to treatment and identifying therapeutic targets that may produce a sustained response in leptomeningeal disease,” said Michael Dugan, MD, medical director and medical director of Biocept. “CNSide has the potential to give clinicians more confidence in their treatment decisions, improving clinical management of leptomeningeal disease in a way that can help patients see improvement in symptoms and live much longer. long time. “

The case series was completed by neuro-oncologists from Smilow Cancer Hospital at Yale New Haven Health, Lou and Jean Malnati Brain Tumor Institute at Northwestern Medicine, UT Southwestern Medical Center and Barrow Neurological Institute. The abstract (# BIOM-05), titled “CNSide ™ Multi-Institutional Utility Case Series for Managing Leptomeningeal Disease in Patients with Metastatic Breast Cancer”, can be accessed here.

About Biocept

Biocept, Inc., develops and markets molecular diagnostic assays that provide clinicians with clinically actionable information to aid in the diagnosis, treatment, and follow-up of cancer patients. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide ™ cerebrospinal fluid test, designed to diagnose cancer that has metastasized to the central nervous system. Biocept is also leveraging its molecular diagnostic capabilities to deliver nationwide RT-PCR-based COVID-19 tests and services to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

Disclaimer Regarding Forward-Looking Statements

This press release contains forward-looking statements based on current expectations or beliefs, as well as a number of assumptions about future events. Although Biocept believes that the expectations reflected in the forward-looking statements and the assumptions on which they are based are reasonable, Biocept cannot guarantee that these expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words such as “may”, “will”, “could”, “expect” or “believe” or by the negative of these words or other variations of these words. or comparable terminology. To the extent that the statements in this release are not strictly historical, including, but not limited to, statements regarding the capabilities and potential benefits of Biocept’s CNSide test and the ability of Biocept’s tests to provide Physicians’ clinically practical information, these statements are forward-looking and comply with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements as these statements are subject to many risks and uncertainties, including the risk that Biocept’s products and services may not perform as intended. These and other risks are described in more detail under the heading “Risk Factors” of Biocept’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission (SEC) on November 15, 2021. The effects of these risks and uncertainties could cause the actual results of Biocept to differ materially from the forward-looking statements contained in this press release. Biocept does not intend to update these forward-looking statements and expressly disclaims any obligation to update the information contained in this press release, except as required by law. Readers are referred to the documents filed by Biocept with the SEC, which can be found on the Internet at the SEC’s website at www.sec.gov.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211118005445/en/

Contacts

Media contact:
Andrea Sampson, Sampson Public Relations Group
[email protected], 562-304-0301

Investor contact:
Jody Cain, LHA Investor Relations
[email protected], 310-691-7100

Share.

Comments are closed.